Rationale {#Sec1}
=========

A significant proportion of adults diagnosed with cancer will develop brain metastases. According to the 2008 American Cancer Society Registry, approximately 1.4 million Americans are diagnosed with cancer every year \[[@CR1]\] and up to 40% of these patients---over a half million people annually---will go onto develop one or more brain metastases \[[@CR2]\]. Of these patients, approximately one-third will be potential candidates for surgical resection.

The outcome for patients with brain metastases is generally poor, with median survivals following WBRT alone in the range of 3--6 months \[[@CR3]--[@CR5]\]. Given this poor prognosis, considerable efforts have been made to explore additional or alternative treatment modalities that have the potential to improve survival, quality of life and local tumor control.

For patients with a single accessible brain metastasis, surgical resection followed by post-operative WBRT has been compared to WBRT alone in three randomized control trials (RCTs) \[[@CR3]--[@CR5]\]. The evidence for this combined treatment approach is reviewed in the guideline paper in this series by Gaspar et al. \[[@CR6]\] Because the data from these randomized comparisons of WBRT alone, versus surgical resection followed by post-operative WBRT, addresses the role of surgical resection in the management of patients with a newly diagnosed brain metastasis, this paper will refer to this evidence in its recommendations for the role of surgical resection.

The advent of stereotactic radiosurgery (SRS) has provided a new and less invasive local treatment modality that, like surgical resection, has the ability to treat brain metastases while sparing healthy brain tissue. A key area that this paper will address is the role of surgical resection compared to SRS in the initial management of patients with brain metastases.

The overall objectives of this paper are:To systematically review the evidence available for the following treatment comparisons for patients with a newly diagnosed brain metastasis. Please note that "surgery" implies open surgical resection.Surgery versus WBRT ± surgerySurgery ± WBRT or partial brain radiotherapy (RT) versus SRS ± WBRT or partial brain RTSurgery ± WBRT versus surgery + SRSTo make recommendations based on this evidence for the role of surgery in the management of these patients.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

The following electronic databases were searched from 1990 to September 2008: MEDLINE^®^, Embase^®^, Cochrane Database of Systematic Reviews, Cochrane Controlled Trials Registry, and Cochrane Database of Abstracts of Reviews of Effects. A broad search strategy using a combination of subheadings and text words was employed. The search strategy is documented in the methodology paper for this guideline series by Robinson et al. \[[@CR7]\]. Reference lists of included studies were also reviewed.

Eligibility criteria {#Sec4}
--------------------

Published in English.Patients with newly diagnosed brain metastases.Fully-published (i.e., not in abstract form) peer-reviewed primary comparative studies (These included the following comparative study designs for primary data collection: RCTs, non-randomized trials, cohort studies and case--control studies).Study comparisons include one or more of the following:Surgery versus WBRTSurgery versus surgery + WBRTSurgery ± WBRT or partial brain RT versus SRS ± WBRT or partial brain RTSurgery versus surgery + SRSSurgery + WBRT versus surgery + SRS(Where SRS could be single session and fractionated stereotactic radiotherapy)Number of study participants with a newly diagnosed brain metastasis ≥5 per study arm for at least two of the study arms.Baseline information on study participants is provided by treatment group in studies evaluating interventions exclusively in patients with a newly diagnosed brain metastasis. For studies with mixed populations (i.e., includes participants with conditions other than newly diagnosed brain metastases), baseline information is provided for the intervention sub-groups of participants with a newly diagnosed brain metastasis.

Study selection and quality assessment {#Sec5}
--------------------------------------

Two independent reviewers evaluated citations using a priori criteria for relevance and documented decisions in standardized forms. Cases of disagreement were resolved by a third reviewer. The same methodology was used for full-text screening of potentially relevant papers. Studies which met the eligibility criteria were data extracted by one reviewer and the extracted information was checked by a second reviewer. The PEDro scale \[[@CR8], [@CR9]\] was used to rate the quality of randomized trials. The quality of comparative studies using non-randomized designs was evaluated using eight items selected and modified from existing scales.

Evidence classification and recommendation levels {#Sec6}
-------------------------------------------------

Both the quality of the evidence and the strength of the recommendations were graded according to the American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) criteria. These criteria are provided in the methodology paper for this guideline series.

Guideline development process {#Sec7}
-----------------------------

The AANS/CNS convened a multi-disciplinary panel of clinical experts to develop a series of practice guidelines on the management of brain metastases based on a systematic review of the literature conducted in collaboration with methodologists at the McMaster University Evidence-based Practice Center.

Scientific foundation {#Sec8}
=====================

Overall, 15 publications (14 primary studies \[[@CR10]--[@CR23]\] and one companion paper \[[@CR24]\]) met the eligibility criteria. Figure [1](#Fig1){ref-type="fig"} outlines the flow of studies through the review process.Fig. 1Flow of studies to final number of eligible studies

Surgical resection versus surgical resection + WBRT {#Sec9}
---------------------------------------------------

One RCT \[[@CR10]\] and three retrospective cohort studies \[[@CR11]--[@CR13]\] evaluated surgical resection alone compared to surgery plus post-operative WBRT for the initial management of a single brain metastasis (Table [1](#Tab1){ref-type="table"}).Table 1Surgery versus surgery + WBRTFirst author (Year)InterventionsMedian survival\# pts with recurrence/progression^a^Median time to recurrence/progressionRandomized trials Patchell \[[@CR10]\] (1998)G1: Surgery (*n* = 46)\
G2: Surgery + WBRT (*n* = 49)G1: 43 wks\
G2: 48 wks\
(Log-rank; *P* = NS)At original site:\
G1: 21/46 (46%)\
G2: 5/49 (10%) (*P* \< 0.001)\
Overall in brain:\
G1: 32/46 (70%)\
G2: 9/49 (18%) (*P* \< 0.001)At original site:\
G1: 27 wks\
G2: \> 50 wks (Log-rank; *P* \< 0.001)\
Overall in brain:\
G1: 26 wks\
G2: 220 wks (Log-rank; *P* \< 0.001)Retrospective cohort studies Armstrong\[[@CR11]\] (1994)G1: Surgery (*n* = 32)\
G2: Surgery + WBRT (*n* = 32)\
\[matched to G1\]\
G3: Surgery + \
WBRT (*n* = 79)\
\[not matched\]G1: 14 months\
G2: 10 months\
G3: 15 months\
(G1 vs. G2:\
Log-rank; *P* = NS)At original site:\
G1: 11/32 (34%)\
G2 + G3: 25/111 (23%)\
(G1 vs. G2 + G3: *P* = NS)\
Overall in brain:\
G1: 38%\
G2: 47%\
G3: 42% (G1 vs. G2: *P* = NS)NRHagen \[[@CR12]\] (1990)G1: Surgery (*n* = 16)\
G2: Surgery + WBRT (*n* = 19)G1: 8.3 months\
G2: 6.4 months\
(Test not specified; *P* = NS)At original site:\
G1: 6/16 (38%)\
G2: 4/19 (21%) (*P* = NR)\
Overall in brain:\
G1: 11/16 (69%)\
G2: 7/19 (37%) (*P* = NR)At original site: NR\
Overall in brain:\
G1: 5.7 months\
G2: 26.6 months\
(Test not specified; *P* \< 0.05)Skibber \[[@CR13]\] (1996)G1: Surgery (*n* = 12)\
G2: Surgery + WBRT (*n* = 22)G1: 6 months\
G2: 18 months\
(Generalized Wilcoxon; *P* = 0.002)At original site: NR\
Overall in brain:\
G1: 9/12 (75%)\
G2: 5/22 (23%) (*P* = NR)NR*G1* Group 1, *G2* Group 2, *G3* Group 3, *NR* Not reported, *NS* Not significant, *Pts* Patients, *WBRT* Whole-brain radiation therapy^a^Number of pts with recurrence/progression of brain metastases, unless otherwise specified

The randomized data available to address this treatment comparison comes from a multi-center trial conducted in the United States by Patchell et al. \[[@CR10]\]. The trial randomized adults with Karnofsky performance scores (KPS) ≥70 who had complete resection of a single biopsy-proven brain metastasis, confirmed by MRI, to post-operative WBRT (50.4 Gy in 28 fractions) or no further treatment. Randomization was stratified by the extent of extra-cranial disease and primary tumor type. A total of 95 patients were randomized: 49 patients to post-operative WBRT and 46 patients to observation. Baseline characteristics were well-balanced between the two groups. Non-small cell lung cancer (NSCLC) was the predominant tumor type (surgery + WBRT: 59%; surgery alone: 61%), median KPS was 90 in both groups and approximately one-third of patients had no evidence of extra-cranial disease (surgery + WBRT: 37%; surgery alone: 35%). No patient was lost to follow-up and the data was analyzed by intention-to-treat. The primary outcome was tumor recurrence anywhere in the brain.

Fewer patients who received post-operative WBRT experienced a recurrence in the brain compared to those who had surgical resection alone \[surgery + WBRT: 9/49 (18%) versus surgery: 32/46 (70%); *P* \< 0.001\]. Recurrence in the WBRT group was less frequent both at the original site of the brain metastasis \[surgery + WBRT: 5/49 (10%) versus surgery: 21/46 (46%); *P* \< 0.001\] and at distant sites in the brain \[surgery + WBRT: 7/49 (14%) versus surgery: 17/46 (37%); *P* \< 0.01\] compared to patients who did not receive post-operative WBRT.

The time to any recurrence in the brain was significantly longer in the group that had post-operative WBRT compared to the group that did not (log-rank; *P* \< 0.001). Both the time to recurrence at the original site in the brain (log-rank; *P* \< 0.001) and at distant brain sites (log-rank; *P* = 0.04) were significantly longer in the post-operative WBRT group compared to the group that received no further treatment following surgery.

Fewer patients in the WBRT group died as a result of neurological causes than did patients in the surgery alone group \[surgery + WBRT: 6/43 (14%) deaths versus surgery: 17/39 (44%) deaths; *P* = 0.003\]. Overall survival did not differ significantly between the two groups. Median survival in the surgery + WBRT group was 48 weeks compared to 43 weeks in the group that received no further treatment following surgical resection. This study was not powered for survival, however, which was a secondary and not a primary endpoint. The duration of functional independence (defined as the median time that KPS remain ≥70) also did not differ significantly between the two groups (surgery + WBRT: 37 weeks versus surgery: 35 weeks; *P* = NS).

Surgical resection ± WBRT or partial brain RT versus stereotactic radiosurgery (SRS) ± whole or partial brain RT {#Sec10}
----------------------------------------------------------------------------------------------------------------

One RCT \[[@CR23]\] and nine retrospective cohort studies \[[@CR14]--[@CR22]\] met the eligibility criteria for this treatment comparison (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}). All of these studies utilized single-dose SRS with one exception \[[@CR20]\] which employed fractionated stereotactic radiotherapy. However, in 2006, the American Society for Therapeutic Radiology and Oncology (ASTRO), the American Association of Neurological Surgeons (AANS) and the Congress of Neurological Surgeons (CNS) jointly agreed to define SRS in a way that includes both traditional single dose SRS, as well as multi-dose SRS up to five doses (2--5 doses) \[[@CR25], [@CR26]\]. Additionally, while the majority of these SRS studies were conducted using Gamma Knife radiosurgery, there is no evidence to suggest that other modes of delivery of SRS would lead to different outcomes.Table 2SRS versus Surgery + WBRTFirst author (Year)InterventionsMedian survival\# pts with recurrence/progression^a^Median time to recurrence/progressionRandomized controlled trials Muacevic \[[@CR23]\] (2008)G1: SRS (*n* = 31)\
G2: Surgery + WBRT (*n* = 33)G1: 10.3 months\
G2: 9.5 months\
(Log-rank; *P* = NS)1 yr local control rate:\
G1: 97%\
G2: 82%\
1 yr distant recurrence rate:\
G1: 26%\
G2: 3%At original site:\
Median: NR\
(LR curves: log-rank; *P* = 0.06, NS)\
At distant brain sites:\
Median: NR\
(DR curves: log-rank; *P* = 0.04)Retrospective cohort studies Muacevic \[[@CR14]\] (1999)G1: SRS (*n* = 56)\
G2: Surgery + WBRT (*n* = 52)G1: 35 weeks\
G2: 68 weeks\
(Log-rank; *P* = NS)1 yr freedom from LR rate:\
G1: 83%\
G2: 75%\
1 yr freedom from DR rate:\
G1: 68%\
G2: 90% (*P* = 0.0025)At original site:\
G1: Median not reached\
G2: Median not reached\
(Log-rank; *P* = NS)\
At distant brain sites:\
NR Rades \[[@CR15]\] (2007)G1: SRS (*n* = 94)Median survival: NR1 yr freedom from LR rate:At original site:G2: Surgery + WBRT (*n* = 112)1 yr survival rate:\
G1: 54%\
G2: 38%\
(Log-rank; *P* = NS)G1: 64%\
G2: 56%\
1 yr freedom from BR rate:\
G1: 49%\
G2: 44%Median: NR\
(LR curves: log-rank; *P* = NS)\
Overall in brain:\
Median: NR\
(BR curves: log-rank; *P* = NS)*BR* Brain recurrence (local + distant), *DR* Distant recurrence in brain, *G1* Group 1, *G2* Group 2, *LR* Local recurrence at original site in brain, *NR* Not reported, *NS* Not significant, *Pts* Patients, *SRS* Stereotactic radiosurgery, *WBRT* Whole-brain radiation therapy^a^Number of pts with recurrence/progression of brain metastases, unless otherwise specifiedTable 3Surgery + WBRT versus SRS + WBRTFirst author (Year)InterventionsMedian survival\# pts with recurrence/progression^a^Median time to recurrence/progressionRetrospective cohort studies Bindal \[[@CR16]\] (1996)G1: Surgery ± WBRT^b^ (*n* = 62) \[matched to G2\]\
G2: SRS ± WBRT^b^ (*n* = 31)G1: 16.4 months\
G2: 7.5 months\
(Log-rank; *P* = 0.0018)1 yr freedom from LR rate:\
G2 poorer than G1\
\[Data: NR\]\
1 yr freedom from DR rate:\
G1: 75%\
G2: 69%At original site:\
G1: Median not reached\
G2: 6 months\
(Log-rank; *P* = 0.0001)\
At distant brain sites:\
G1: Median not reached\
G2: Median not reached\
(Log-rank; *P* = NS) Garell \[[@CR17]\] (1999)G1: Surgery + WBRT (*n* = 37)\
G2: SRS + WBRT (*n* = 8)G1: 8 months\
G2: 12.5 months\
(Log-rank *P* = NS)NRNR Schoggl \[[@CR18]\] (2000)G1: Surgery + WBRT (*n* = 66)\
G2: SRS + WBRT (*n* = 67)G1: 9 months\
G2: 12 months\
(Test unclear^;^*P* = NS)At original site:\
G1: 11/66 (17%)\
G2: 3/67 (5%) (*P* = NR)\
At distant brain sites:\
G1: 10/66 (15%)\
G2: 7/67 (10%) (*P* = NR)At original site:\
G1: 3.9 months\
G2: 4.9 months\
(Test unclear; *P* \< 0.05)\
At distant brain sites:\
G1: 3.7 months\
G2: 4.4 months\
(Test unclear; *P* = NS) O'Neill \[[@CR19]\] (2003)G1: Surgery ± WBRT^b^ (*n* = 74)\
G2: SRS ± WBRT^b^ (*n* = 23)Median survival: NR\
1 yr survival rate:\
G1: 62%\
G2: 56%\
(Log-rank; *P* = NS)At original site:\
G1: 11/64 (17%)\
G2: 0/21 (0%) (*P* = NR)\
Overall in brain:\
G1: 19/64 (30%)\
G2: 6/21 (29%) (*P* = NR)NR*DR* Distant recurrence in brain, *G1* Group 1, *G2* Group 2, *LR* Local recurrence at original site in brain, *NR* Not reported, *NS* Not significant, *Pts* Patients, *SRS* Stereotactic radiosurgery, *WBRT* Whole-brain radiation therapy^a^Number of pts with recurrence/progression of brain metastases, unless otherwise specified^b^WBRT use similar at baseline in both groupsTable 4Other included studies of surgery ± radiotherapy versus SRS ± radiotherapyFirst author (year)InterventionsMedian survival\# pts with recurrence/progression^a^Median time to recurrence/progressionRetrospective cohorts Ikushima \[[@CR20]\] (2000)G1: Fractionated SRS (*n* = 10)\
G2: Surgery + RT (*n* = 11)\
G3: RT (*n* = 14)\
\[RT = WBRT or local\]G1: 25.6 months\
G2: 18.7 months\
G3: 4.3 months\
(Univariate analysis:\
G1 vs. G2 + G3: *P* = 0.05)1 yr local control rate:\
G1: 90%\
G2: 88%\
G3: NRAt original site:\
Median: NR\
(LR curves: log-rank; *P* = NS) Shinoura \[[@CR21]\] (2002)G1: SRS (*n* = 28)\
G2: Surgery + RT (*n* = 35)\
\[RT = WBRT or local\]G1: 8.2 months\
G2: 34.4 months\
(Log-rank; *P* \< 0.0001)\# lesions that recurred at original site:\
G1: 16/52 (31%)\
G2: 14/46 (30%)\
(*P*-value: NR)Mean time at original site:\
G1: 7.2 months\
G2: 25 months\
(Log-rank; *P* = 0.0199) Wang \[[@CR22]\] (2002)G1: Surgery\
G2: WBRT\
G3: SRS\
G4: SRS + WBRTG1: 43 wks\
G2: 37 wks\
G3: 67 wks\
G4: 91 wks\
(Log-rank *P* \< 0.00001)1 month local tumor control:\
G1: 89%\
G2: 88%\
G3: 93%\
G4: 96%NR\
.*G1* Group 1, *G2* Group 2, *G3* Group 3, *G4* Group 4, *LR* Local recurrence at original site in brain, *NR* Not reported, *Pts* Patients, *RT* Radiotherapy, *SRS* Stereotactic radiosurgery, *WBRT* Whole-brain radiation therapy^a^Number of pts with recurrence/progression of brain metastases, unless otherwise specified

### (a) Surgical resection + WBRT versus SRS {#Sec20}

A small RCT \[[@CR23]\] and two retrospective cohorts \[[@CR14], [@CR15]\] specifically compared resection plus post-operative WBRT to SRS alone for the initial treatment of a newly diagnosed brain metastasis (Table [2](#Tab2){ref-type="table"}).

The randomized data is from a multi-center RCT conducted in Germany by Muacevic et al. \[[@CR23]\], which closed prematurely due to poor patient accrual. A total of 64 out of the planned 242 adult patients with single, small (≤3 cm) operable brain metastases and a KPS ≥70 were randomized to receive SRS alone (*n* = 31) or surgical resection followed by WBRT (*n* = 33). Baseline prognostic variables were well-balanced between the two groups. All of the participants received the treatment as allocated and none were lost to follow-up.

The primary outcome, overall survival, did not differ significantly between the two groups. Median survival in the surgery + WBRT group was 9.5 months, compared to 10.3 months in the group that received SRS. In terms of secondary outcomes, duration of freedom from local recurrence did not significantly differ between the two groups (log-rank; *P* = 0.06; NS). The 1 year local control rate was 82% in the surgery + WBRT group and 96.8% in the SRS group. Freedom from recurrence at distant brain sites was significantly longer in the group that had surgical resection plus WBRT compared to the group that received SRS (log-rank; *P* = 0.04). Finally, the overall number of neurological deaths was not significantly different between the groups.

### (b) Surgical resection + WBRT versus SRS + WBRT {#Sec100}

No prospective studies were identified that met the eligibility criteria for this treatment comparison. Four retrospective cohort studies \[[@CR16]--[@CR19]\] that compared surgical resection plus WBRT to SRS plus WBRT met the inclusion criteria (Table [3](#Tab3){ref-type="table"}). In two of these studies \[[@CR16], [@CR19]\] the majority, but not all, of the subjects received WBRT.

In three of the studies \[[@CR17]--[@CR19]\], overall survival did not differ significantly between the resection plus WBRT group compared with the group that received SRS plus WBRT. In one study \[[@CR16]\], overall survival was significantly longer for patients that received surgery plus WBRT compared to patients that had SRS and WBRT (log-rank; *P* = 0.0018), although patients in the SRS arm were generally poorer resection candidates. In this study, freedom from local recurrence was also significantly longer in the surgery plus WBRT group (log-rank; *P* = 0.0001). Schoggl et al. \[[@CR18]\] reported a significant benefit in duration of freedom from local recurrence for patients that received SRS and WBRT compared to patients that had surgical excision plus WBRT (*P* \< 0.05), supporting the findings in the Garell et al. \[[@CR17]\] study as well. O'Neill et al. \[[@CR19]\] reported no local recurrences in the SRS group compared to a 58% local recurrence rate in the surgical resection group (*P* = 0.020). These studies also demonstrated no significant difference between groups in the duration of freedom from recurrence at *distant* brain sites \[[@CR16], [@CR18]\].

Surgical resection ± WBRT versus surgical resection + SRS {#Sec11}
=========================================================

No studies were identified that met the eligibility criteria for this treatment comparison.

Summary and discussion {#Sec12}
======================

Surgical resection plus WBRT versus WBRT alone {#Sec13}
----------------------------------------------

The WBRT guideline paper by Gaspar et al. \[[@CR6]\] outlines in detail the evidence supporting the addition of WBRT after surgical resection. Please refer to this paper for a further discussion of why surgical resection plus post-operative WBRT represents a superior treatment modality as compared to WBRT alone, in patients with good performance status (functionally independent and spending less than 50% of time in bed) and limited extra-cranial disease. There is insufficient evidence to make a recommendation for patients with poor performance scores, advanced systemic disease, or multiple brain metastases.

Surgical resection + WBRT versus surgical resection {#Sec14}
---------------------------------------------------

Class I evidence is available (in the Patchell RCT \[[@CR10]\]) to support a level 1 recommendation for patients with a single brain metastasis amenable to surgical resection. The class I evidence supports the use of WBRT following surgical resection. Control of extra-cranial disease is not required for patients to benefit from aggressive forms of local therapy, but generally patients required a KPS of at least 70 to be eligible for the studies and the anticipated interventions. Recurrence in the brain, as measured overall, at the original site or at distant brain sites, were all significantly lower in the group that received adjuvant post-operative WBRT than the group undergoing surgical resection alone.

However, both overall survival and time spent in an independent status (KPS \>70) did not differ significantly between the groups. The Patchell study did show a reduction in neurologic deaths (*P* = 0.003) in the patients who received WBRT in addition to surgical resection. In patients with distant metastatic disease, rates of neurological death may in fact provide a more useful endpoint for this clinical comparison. Nonetheless, the lack of a survival difference has offered support to a common but unsubstantiated treatment plan encompassing surgery alone with close observation, delaying WBRT for so-called "salvage therapy" at recurrence. No evidence-based justification currently exists for such expectant observation.

Surgical resection + WBRT versus SRS {#Sec15}
------------------------------------

While the surgical resection versus radiosurgery comparison produces less clear-cut results, class I evidence based on the AANS/CNS scale does address this clinical question. However, the Muacevic RCT \[[@CR23]\] closed early and only enrolled approximately one-quarter of the proposed participants and was thus underpowered to detect a survival difference, if in fact one exists. Given the small sample size, the authors of the RCT reported that by their calculations, the trial was only sufficiently powered to detect an overall survival difference of 38% or greater between the two groups 80% of the time. It is difficult to offer firm guidelines based upon a prematurely closed study.

Furthermore, duration of freedom from local recurrence did not significantly differ between the two groups (log-rank; *P* = 0.06; NS) with the 1 year local control rate at 82% in the resection + WBRT group and 96.8% in the SRS group. A larger trial will, perhaps, provide more definitive information regarding this outcome given the borderline *P*-value of 0.06. In general, though, it is often difficult to determine local recurrence in a study comparing surgical resection versus SRS; in the SRS literature, a remaining enhancing abnormality stable over time is considered "local control," but may overestimate the true long-term control associated with SRS.

In terms of distant brain recurrence, freedom from recurrence at distant brain sites was significantly longer in the group that had resection plus WBRT, as expected, compared to the group that received local therapy in the form of SRS (log-rank; *P* = 0.04). In this and other studies, patient accrual lagged behind proposed enrollment in the study design phase because of strong physician preference for either surgical resection or SRS.

The lower distant brain recurrence rates in the WBRT arm makes intuitive sense since these patients are receiving effective treatment for potential lesions elsewhere in the brain, unlike those in the SRS arm. In terms of survival, however, class II evidence suggests that survival is not decreased when WBRT is not given as initial therapy (for details, refer to the guideline paper in this series by Linskey et al. \[[@CR27]\], which addresses the role of SRS for newly diagnosed brain metastases).

Quality of life, including potential neuro-cognitive treatment effects, represents another important question that still needs to be addressed: does recurrence impact quality of life since survival appears to be unchanged between the two treatment arms? A recently-closed randomized Phase III trial by the European Organization for the Research and Treatment of Cancer (EORTC \#22952) achieved full accrual of its target 340 patients and compared no radiotherapy to WBRT for 1--3 brain metastases from solid tumor after resection or SRS; these results, when available, may provide powerful evidence for the role of WBRT.

Surgical resection + WBRT versus SRS + WBRT {#Sec16}
-------------------------------------------

Four retrospective cohort studies \[[@CR16]--[@CR19]\] provide evidence for this treatment comparison. While class II evidence does exist for these interventions, all of the studies are retrospective rather than prospective, and they yield conflicting results in terms of overall survival and duration of freedom from local recurrence. However, Class II evidence does suggest that larger lesions (\>3 cm in maximum diameter) or those causing significant mass effect (\>1 cm midline shift) may have better outcomes with surgical resection. Radiosurgery is recommended for single surgically inaccessible lesions measuring \<3 cm in maximum diameter.

Surgical resection ± WBRT versus surgical resection + SRS {#Sec17}
---------------------------------------------------------

No studies were identified for this treatment comparison and as such, no evidence-based recommendations can be made regarding one approach compared to the other.

Conclusions and future directions {#Sec18}
=================================

Class I evidence suggests that surgical resection followed by WBRT represents a superior treatment modality, in terms of improving tumor control at the original site of the metastasis and in the brain overall, when compared to surgical resection alone. As reviewed by Gaspar et al., in the WBRT guideline paper in this series, class I evidence also supports the use of surgical resection plus post-operative WBRT in patients with good performance status and limited extra-cranial disease compared to WBRT alone (refer to the WBRT guideline paper in this series for further detail).

The advent of SRS, though, has provided several clinically important permutations and combination treatment options for patients with brain metastases, some of which clearly improve recurrence rates and survival as well. Guideline papers in this series by Gaspar et al., and Linskey et al., address some of these relevant treatment comparisons incorporating surgical resection, WBRT, SRS and the concept of delaying WBRT for salvage therapy without adverse sequelae. Class II evidence suggests that larger lesions (\>3 cm) or those causing significant mass effect (\>1 cm midline shift) may have better outcomes with surgical resection, whereas radiosurgery may offer slightly better local control rates for radioresistant lesions (i.e., melanoma, renal cell, etc.). However, because of underpowered class I evidence in the resection + WBRT versus SRS alone comparison, the authors could only make a level 3 recommendation suggesting that SRS *alone* may provide equivalent functional and survival outcomes compared with resection + WBRT for patients with single brain metastases, so long as ready detection of distant site failure and salvage SRS are possible.

Additional prospective randomized studies, such as the Phase 3 EORTC study mentioned previously (referenced below---5) and two recently closed randomized trials comparing surgical resection to SRS (referenced below---1, 2), will be required to more definitively assess treatment outcomes.

One notable treatment combination in need of further study involves the concept of applying SRS to the surgical resection cavity post-operatively instead of post-operative WBRT. Although many large cancer centers around the country have recently adopted this practice, no robust prospective data yet exists to support a few retrospective case series suggesting that both local control rates and even survival are enhanced by this post-operative SRS option.

The role of surgical resection for multiple brain metastases {#Sec19}
------------------------------------------------------------

While surgical resection of more than one brain metastasis has been performed in cases of significant mass effect from more than one lesion, and in cases where two or more lesions are accessible through the same craniotomy approach, no robust comparative data exists to evaluate the role of surgical resection for multiple brain metastases. Future studies incorporating the role of resection for more than one brain metastasis, with or without additional adjuvant therapy, will also help clarify whether the benefits of resection discussed above apply to multiple lesions.

Other important future directions include designing trials with a focus on quality of life and patient functional status as primary outcomes, rather than only recurrence rates or survival. Given that small differences in survival rates for a given treatment option potentially minimize significant differences in quality of life for a particular therapy, an analysis of a wider range of outcome parameters may help better inform practitioners, and our patients, when making critical treatment decisions. Histology-specific brain metastasis trials may also help answer important therapeutic questions regarding radioresistant lesions versus other common histologies. Most studies thus far have not specifically addressed differences in histological subtype despite the fact that management of extracranial malignancies differs widely based on cancer histology (i.e., breast versus lung versus renal cell, etc.).

The following is a list of major ongoing or recently closed clinical trials pertaining to the use of surgery that evaluate treatment comparisons addressed by this guideline paper for the management of newly diagnosed brain metastases.Surgery versus radiosurgery to treat metastatic brain tumors**Official Title:** A Prospective, Randomized Trial Comparing Surgery Versus Radiosurgery for the Treatment of Metastatic Brain Tumors**Status:** Completed**Clinicaltrials.gov Identifier:** NCT00075166**Location:** United States**Sponsors and Collaborators:** National Institute of Neurological Disorders and Stroke (NINDS)2. Surgery versus stereotactic radiosurgery in the treatment of single brain metastasis: a randomized trial**Official Title:** Surgery Versus Stereotactic Radiosurgery in the Treatment of Single Brain Metastasis: A Randomized Trial**Status:** Completed**Clinicaltrials.gov Identifier:** NCT00460395**Principal Investigator:** Frederick F. Lang, M.D., University Of Texas MD Anderson Cancer Center**Location:** United States**Sponsors and Collaborators:** M.D. Anderson Cancer CenterA Trial of Postoperative Whole Brain Radiation Therapy versus Salvage Stereotactic Radiosurgery Therapy for Metastasis**Official Title:** Randomized Phase III Trial of Postoperative Whole Brain Radiation Therapy Compared With Salvage Stereotactic Radiosurgery in Patients With One to Four Brain Metastasis: Japan Clinical Oncology Group Study (JCOG 0504)**Status:** Recruiting (Phase III)**Clinicaltrials.gov Identifier:** NCT00280475**Principal Investigator:** Takamasa Kayama, MD, PhD Yamagata University Faculty of Medicine**Location:** Japan (21 locations)**Sponsors and Collaborators:** Japan Clinical Oncology Group, Japanese Ministry of Health, Labor and WelfareA Trial Comparing Radiosurgery With Surgery for Solitary Brain Metastases**Official Title:** A Randomised Trial of Surgery Plus Whole Brain Radiotherapy (WBRT) Versus Radiosurgery Plus WBRT for Solitary Brain Metastases**Status:** Recruiting (Phase III)**Clinicaltrials.gov Identifier:** NCT00124761Principal Investigator: Daniel Roos, FRANZCR, Royal Adelaide Hospital**Location:** Australia**Sponsors and Collaborators:** Royal Adelaide HospitalAdjuvant Radiation Therapy in Treating Patients With Brain Metastases**Official Title:** Phase III Trial on Convergent Beam Irradiation of Cerebral Metastases**Status:** Active, not recruiting (Phase III)**Clinicaltrials.gov Identifier:** NCT00002899**Principal Investigators:** Rolf-Peter Mueller, MD Medizinische Universitaetsklinik I at the University of Cologne Riccardo Soffietti, MD Universita Degli Studi di Turin**Location:** Europe (33 locations)**Sponsors and Collaborators:** European Organization for Research and Treatment of Cancer
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